Drugs / MUC-2-Globo H-KLH conjugate vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00036933 | Mar 2002 → Mar 2009 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00016146 | Jul 2000 → Mar 2009 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC-2-Globo H-KLH conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00036933 ↗ |
| Modality | Vaccine | “glycosylated MUC-2-Globo H-KLH conjugate vaccine” NCT00016146 ↗ |
| Route | Subcutaneous | “Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26” NCT00016146 ↗ |